Journal
SCIENCE
Volume 375, Issue 6583, Pages 877-+Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abl5447
Keywords
-
Categories
Funding
- Center for Cancer Research intramural research program of the National Cancer Institute
- CCR Single Cell Analysis Facility - FNLCR [HHSN261200800001E]
- National Cancer Institute, National Institutes of Health [75N91019D00024]
Ask authors/readers for more resources
Mapping TCRs from metastatic tumors to single-cell transcriptomes identified tumor-specific expanded neoantigen-specific TILs with dysfunctional phenotypes. Prospectively testing signature-derived clonotypes demonstrated TCR recognition of tumor antigens, suggesting a common metastatic TIL exhaustion program. NeoTCR signatures enable successful TCR prediction for cancer immunotherapy based on TIL transcriptomic states.
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures of CD8(+) and CD4(+) neoantigen-reactive tumor-infiltrating lymphocytes (TILs). Neoantigen-specific TILs exhibited tumor-specific expansion with dysfunctional phenotypes, distinct from blood-emigrant bystanders and regulatory TILs. Prospective prediction and testing of 73 NeoTCR signature-derived clonotypes demonstrated that half of the tested TCRs recognized tumor antigens or autologous tumors. NeoTCR signatures identified TCRs that target driver neoantigens and nonmutated viral or tumor-associated antigens, suggesting a common metastatic TIL exhaustion program. NeoTCR signatures delineate the landscape of TILs across metastatic tumors, enabling successful TCR prediction based purely on TIL transcriptomic states for use in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available